Literature DB >> 19533811

Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients.

Angèle P M Kerckhoffs1, Melvin Samsom, Michel E van der Rest, Joris de Vogel, Jan Knol, Kaouther Ben-Amor, Louis M A Akkermans.   

Abstract

AIM: To determine the composition of both fecal and duodenal mucosa-associated microbiota in irritable bowel syndrome (IBS) patients and healthy subjects using molecular-based techniques.
METHODS: Fecal and duodenal mucosa brush samples were obtained from 41 IBS patients and 26 healthy subjects. Fecal samples were analyzed for the composition of the total microbiota using fluorescent in situ hybridization (FISH) and both fecal and duodenal brush samples were analyzed for the composition of bifidobacteria using real-time polymerase chain reaction.
RESULTS: The FISH analysis of fecal samples revealed a 2-fold decrease in the level of bifidobacteria (4.2 +/- 1.3 vs 8.3 +/- 1.9, P < 0.01) in IBS patients compared to healthy subjects, whereas no major differences in other bacterial groups were observed. At the species level, Bifidobacterium catenulatum levels were significantly lower (6 +/- 0.6 vs 19 +/- 2.5, P < 0.001) in the IBS patients in both fecal and duodenal brush samples than in healthy subjects.
CONCLUSION: Decreased bifidobacteria levels in both fecal and duodenal brush samples of IBS patients compared to healthy subjects indicate a role for microbiotic composition in IBS pathophysiology.

Entities:  

Mesh:

Year:  2009        PMID: 19533811      PMCID: PMC2699007          DOI: 10.3748/wjg.15.2887

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  46 in total

1.  A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics.

Authors:  Weihong Liu; David A Saint
Journal:  Anal Biochem       Date:  2002-03-01       Impact factor: 3.365

2.  Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.

Authors:  M Pimentel; E J Chow; H C Lin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

3.  A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome.

Authors:  K Niedzielin; H Kordecki; B Birkenfeld
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-10       Impact factor: 2.566

4.  Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora.

Authors:  A Suau; V Rochet; A Sghir; G Gramet; S Brewaeys; M Sutren; L Rigottier-Gois; J Doré
Journal:  Syst Appl Microbiol       Date:  2001-04       Impact factor: 4.022

5.  Molecular analysis of the microbial diversity present in the colonic wall, colonic lumen, and cecal lumen of a pig.

Authors:  S E Pryde; A J Richardson; C S Stewart; H J Flint
Journal:  Appl Environ Microbiol       Date:  1999-12       Impact factor: 4.792

6.  Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome.

Authors:  S Nobaek; M L Johansson; G Molin; S Ahrné; B Jeppsson
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

Review 7.  Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome.

Authors:  Henry C Lin
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

8.  Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects.

Authors:  Emma J Woodmansey; Marion E T McMurdo; George T Macfarlane; Sandra Macfarlane
Journal:  Appl Environ Microbiol       Date:  2004-10       Impact factor: 4.792

9.  Probiotics in the treatment of irritable bowel syndrome.

Authors:  Alfredo Saggioro
Journal:  J Clin Gastroenterol       Date:  2004-07       Impact factor: 3.062

10.  The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects.

Authors:  Anna Kassinen; Lotta Krogius-Kurikka; Harri Mäkivuokko; Teemu Rinttilä; Lars Paulin; Jukka Corander; Erja Malinen; Juha Apajalahti; Airi Palva
Journal:  Gastroenterology       Date:  2007-04-14       Impact factor: 22.682

View more
  98 in total

Review 1.  Microbial activation of gut dendritic cells and the control of mucosal immunity.

Authors:  Jennifer L Owen; Mansour Mohamadzadeh
Journal:  J Interferon Cytokine Res       Date:  2013-08-20       Impact factor: 2.607

2.  Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease.

Authors:  Min Xu; Baohong Wang; Yiqi Fu; Yanfei Chen; Fengling Yang; Haifeng Lu; Yunbo Chen; Jiali Xu; Lanjuan Li
Journal:  Microb Ecol       Date:  2011-08-04       Impact factor: 4.552

Review 3.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

Review 4.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 5.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

Review 6.  An Overview and Proposed Research Framework for Studying Co-Occurring Mental- and Physical-Health Dysfunction.

Authors:  Sarah L Hagerty; Jarrod M Ellingson; Timothy B Helmuth; L Cinnamon Bidwell; Kent E Hutchison; Angela D Bryan
Journal:  Perspect Psychol Sci       Date:  2019-06-07

Review 7.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

Review 8.  Intestinal microbiota and its role in irritable bowel syndrome (IBS).

Authors:  Lena Ohman; Magnus Simrén
Journal:  Curr Gastroenterol Rep       Date:  2013-05

Review 9.  Upper gastrointestinal microbiota and digestive diseases.

Authors:  Zi-Kai Wang; Yun-Sheng Yang
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

10.  New and Emerging Treatment Options for Irritable Bowel Syndrome.

Authors:  Brian E Lacy; William D Chey; Anthony J Lembo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.